Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Conformis, Inc. stock logo
CFMS
Conformis
$2.26
$2.25
$1.05
$7.25
$17.80M1.3999,585 shs7,000 shs
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
$5.89
+9.9%
$5.26
$4.22
$8.90
$67.44M0.248,058 shs5,873 shs
Histogenics Corp stock logo
HSGX
Histogenics
$1.18
$1.33
$0.08
$1.43
$111.63M3.19.06 million shs6.86 million shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Conformis, Inc. stock logo
CFMS
Conformis
0.00%0.00%0.00%0.00%+56.94%
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
-0.92%+2.29%+2.29%+7.20%-23.43%
Histogenics Corp stock logo
HSGX
Histogenics
0.00%-10.61%-31.79%+105.18%+63.89%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Conformis, Inc. stock logo
CFMS
Conformis
N/AN/AN/AN/AN/AN/AN/AN/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
2.5684 of 5 stars
3.55.00.00.02.60.00.6
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Conformis, Inc. stock logo
CFMS
Conformis
2.00
HoldN/AN/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
3.00
Buy$11.0086.76% Upside
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/A

Current Analyst Ratings

Latest CFMS, CLGN, and HSGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/5/2024
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Conformis, Inc. stock logo
CFMS
Conformis
$57.06M0.31N/AN/A$4.07 per share0.56
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
$10.96M6.15N/AN/A$2.47 per share2.38
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/A($0.01) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Conformis, Inc. stock logo
CFMS
Conformis
-$50.47M-$5.61N/AN/AN/A-72.72%-86.46%-47.65%N/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
-$7.02M-$0.64N/AN/AN/A-64.05%-22.17%-18.84%5/22/2024 (Estimated)
Histogenics Corp stock logo
HSGX
Histogenics
-$8.64M-$0.79N/AN/AN/A-34.96%18.40%N/A

Latest CFMS, CLGN, and HSGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/4/2024Q4 2023
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/A-$0.42-$0.42-$0.42N/A$0.30 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Conformis, Inc. stock logo
CFMS
Conformis
N/AN/AN/AN/AN/A
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/AN/AN/AN/AN/A
Histogenics Corp stock logo
HSGX
Histogenics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Conformis, Inc. stock logo
CFMS
Conformis
0.64
5.07
3.30
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
N/A
8.62
8.40
Histogenics Corp stock logo
HSGX
Histogenics
N/A
4.05
4.05

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Conformis, Inc. stock logo
CFMS
Conformis
10.31%
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
21.69%
Histogenics Corp stock logo
HSGX
Histogenics
40.35%

Insider Ownership

CompanyInsider Ownership
Conformis, Inc. stock logo
CFMS
Conformis
3.80%
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
9.60%
Histogenics Corp stock logo
HSGX
Histogenics
19.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Conformis, Inc. stock logo
CFMS
Conformis
2957.88 million7.58 millionNot Optionable
CollPlant Biotechnologies Ltd. stock logo
CLGN
CollPlant Biotechnologies
7311.45 million10.35 millionOptionable
Histogenics Corp stock logo
HSGX
Histogenics
4994.60 millionN/ANot Optionable

CFMS, CLGN, and HSGX Headlines

SourceHeadline
Knee Cartilage Repair Market Size, Development Data, Growth ... - StreetBuzzKnee Cartilage Repair Market Size, Development Data, Growth ... - StreetBuzz
news.google.com - May 12 at 10:47 PM
Feargal Sharkey: Desperate revival of failed policies doesn’t add upFeargal Sharkey: Desperate revival of failed policies doesn’t add up
thetimes.co.uk - April 8 at 12:08 AM
Global Knee Cartilage Repair Market Analysis And Trends By Segmentations, Top Key Players, Geographical Expans - openPRGlobal Knee Cartilage Repair Market Analysis And Trends By Segmentations, Top Key Players, Geographical Expans - openPR
news.google.com - March 10 at 6:53 AM
Ocugen (OCGN) Q4 2022 Earnings Call Transcript - The Motley FoolOcugen (OCGN) Q4 2022 Earnings Call Transcript - The Motley Fool
news.google.com - February 28 at 11:29 PM
Cartilage Repair Market: Latest Updates, Pros, Cons, And ... - Digital JournalCartilage Repair Market: Latest Updates, Pros, Cons, And ... - Digital Journal
news.google.com - February 27 at 9:35 PM
More Likely to 5x First: Novavax vs. Ocugen - NasdaqMore Likely to 5x First: Novavax vs. Ocugen - Nasdaq
news.google.com - February 16 at 3:39 PM
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell - Nasdaq1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell - Nasdaq
news.google.com - February 5 at 8:38 AM
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell - The Motley Fool1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell - The Motley Fool
news.google.com - February 4 at 9:15 AM
Knee Cartilage Repair Market: Size & Trends Shows a Rapid ... - Digital JournalKnee Cartilage Repair Market: Size & Trends Shows a Rapid ... - Digital Journal
news.google.com - February 3 at 9:38 AM
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer - Yahoo FinanceRallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer - Yahoo Finance
news.google.com - January 31 at 5:18 PM
2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid ... - Nasdaq2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid ... - Nasdaq
news.google.com - January 30 at 10:39 AM
Knee Cartilage Repair Market Trend Shows a Rapid Growth ... - Digital JournalKnee Cartilage Repair Market Trend Shows a Rapid Growth ... - Digital Journal
news.google.com - January 16 at 8:27 AM
NeoCarts Revival Continues as FDA Approves Ocugens Phase III ... - BioSpaceNeoCart's Revival Continues as FDA Approves Ocugen's Phase III ... - BioSpace
news.google.com - December 16 at 12:26 PM
Cartilage Repair Market Expected to Reach USD 2,195 Million, by 2025 - openPRCartilage Repair Market Expected to Reach USD 2,195 Million, by 2025 - openPR
news.google.com - December 15 at 10:13 AM
Knee Cartilage Repair Market 2023 – Globaly Market Size, Analysis, Share, Research, Business Growth and Forecast to 2028 | Top Countries Data - Digital JournalKnee Cartilage Repair Market 2023 – Globaly Market Size, Analysis, Share, Research, Business Growth and Forecast to 2028 | Top Countries Data - Digital Journal
news.google.com - December 6 at 5:42 PM
Knee Cartilage Repair Market is anticipated to Witness Considerable Growth Opportunities to 2030 - Digital JournalKnee Cartilage Repair Market is anticipated to Witness Considerable Growth Opportunities to 2030 - Digital Journal
news.google.com - December 1 at 5:59 AM
Global Knee Cartilage Repair Market Size, Status and Forecast 2022-2028 Market Size 2022 Research Analysis by Share, Growth Rate, Product Types, End Users, Manufactures and Forecast to 2028 - Digital JournalGlobal Knee Cartilage Repair Market Size, Status and Forecast 2022-2028 Market Size 2022 Research Analysis by Share, Growth Rate, Product Types, End Users, Manufactures and Forecast to 2028 - Digital Journal
news.google.com - November 15 at 9:44 AM
Cartilage Repair Market Expected to Reach $2,195 Million, by 2025 | CAGR of 15.0% - openPRCartilage Repair Market Expected to Reach $2,195 Million, by 2025 | CAGR of 15.0% - openPR
news.google.com - November 3 at 9:16 AM
Knee Cartilage Repair Market with Tremendous growth by 2029 - Zimmer Biomet, Smith & Nephew, Stryker - The Knox ReportsKnee Cartilage Repair Market with Tremendous growth by 2029 - Zimmer Biomet, Smith & Nephew, Stryker - The Knox Reports
news.google.com - October 31 at 11:32 AM
Cartilage Repair Market Size Garner to Reach $2,195 Million by 2025 | CAGR of 15.0% - EIN NewsCartilage Repair Market Size Garner to Reach $2,195 Million by 2025 | CAGR of 15.0% - EIN News
news.google.com - October 28 at 3:07 AM
Knee Cartilage Repair Market: Production, Revenue, Price and Gross Margin Analysis with Forecasts to 2030 - openPRKnee Cartilage Repair Market: Production, Revenue, Price and Gross Margin Analysis with Forecasts to 2030 - openPR
openpr.com - October 18 at 12:22 AM
Aspect Biosystems Appoints Three New Board Members - StreetInsider.comAspect Biosystems Appoints Three New Board Members - StreetInsider.com
streetinsider.com - September 21 at 6:25 PM
Aspect Biosystems Appoints Three New Board Members - Business WireAspect Biosystems Appoints Three New Board Members - Business Wire
businesswire.com - September 21 at 1:25 PM
Knee Cartilage Repair Market 2022 Global Regional Overview, Leading Company Analysis, Opportunities, and Forecast to 2028 - Fighting Hawks Magazine - Fighting Hawks MagazineKnee Cartilage Repair Market 2022 Global Regional Overview, Leading Company Analysis, Opportunities, and Forecast to 2028 - Fighting Hawks Magazine - Fighting Hawks Magazine
fightinghawksmagazine.com - September 13 at 5:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Conformis logo

Conformis

NASDAQ:CFMS
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, iTotal CR, and iTotal PS, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also offers Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, Brazil, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
CollPlant Biotechnologies logo

CollPlant Biotechnologies

NASDAQ:CLGN
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Histogenics logo

Histogenics

NASDAQ:HSGX
Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.